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Purpose: The FLEXX trial was a 26-week, double-blind, ran-
domized, saline-controlled study of osteoarthritis (OA) knee pain
treated with an intra-articular (IA) bioengineered 1% sodium
hyaluronate (Euﬂexxa® , IA-BioHA). Patients completing the 26-
week, double-blind phase (core study) were eligible to participate
in the extension phase and received a 3-injection series of IA-
BioHA to evaluate safety. Secondary measures included pain
experienced after a 50-foot walk, the 3 subscales of the WOMAC,
OARSI responder criteria, Patient Global Assessment, use of res-
cue medication, and the SF-36.
Methods: At the ﬁnal visit (week 26) of the core study, all patients
had the option of participating in the open-label extension phase of
the study. Those who elected to participate in this phase received
a once-weekly injection of IA-BioHA into the target knee for 3
weeks (Weeks 26, 27 and 28). Patients returned to the study
center at Weeks 41 and 52 for evaluation. They were also called
by phone at Week 34 or 35 to conﬁrm progress and maintain
contact. The total period of the extension study was 26 weeks,
with 5 clinic visits.
Results: Of the 588 patients (safety population) who participated
in the core study, a total of 433 (73.6%) entered the open-label
extension phase of the FLEXX Trial. The proportions of patients
coming from the core IA-BioHA group [214 (74.7%)] and core
Saline group [219 (72.5%)] were similar, and 87% of both groups
completed the extension. Adverse events were reported in 43% of
both groups. Only 5% were considered IA-BioHA related: arthral-
gias 2.8%, joint swelling 1.2%, peripheral edema 0.7%, injections
site pain 0.5%. There was no difference in adverse reactions
between study groups. No patients reported the treatment emer-
gent adverse event of joint effusion during the extension study.
Retreatment with IA-BioHA was associated with modest further
improvement in pain scores on the 50-foot Walk Test and other
core study measures of efﬁcacy (Table 1).
Table 1. Pain reported following 50-foot walk on a 100mm VAS*
Baseline 26 weeks 28 weeks 41 weeks 52 weeks
IA-BioHA/IA-BioHA 56±22 30±26 22±20 23±24 31±27
*For baseline before ﬁrst injection series and at 26 weeks before second injec-
tion series.
Conclusions: Reinjection with IA-BioHA was well tolerated and
provided a modest further improvement in pain and function from
the ﬁrst injection series over an additional 26 weeks. There was
no difference in adverse event proﬁles for those receiving their ﬁrst
IA-BioHA injection vs. those receiving reinjection.
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Purpose: One of the main events in osteoarthritis is the decrease
in viscosity and elasticity of the synovial ﬂuid, mainly due to
reductions in hyaluronan concentration and molecular weight, and
therefore its ability to protect the joint is lessened. Although several
options are available for the treatment of osteoarthritis, one of the
most important is viscosupplementation, which involves the intra-
articular injection of hyaluronan, restoring synovial ﬂuid viscosity,
thereby reducing pain and recovering function. Hyaluronan is
administered in several affected joints, including the hip. In this
case, iodinated contrast media are used prior to the hyaluronan
injection to verify the correct positioning of the needle in the
intra-articular space. The aim of this study was to determine the
possible interaction between both products and the inﬂuence of
iodinated contrast media on hyaluronan.
Methods: Samples of hyaluronan (molecular weight about 1000
kDa) containing different amounts (0.5, 0.75 and 1 ml) of iodinated
contrast medium (ioxaglate meglumine), with and without previous
incubation for 24 hours at 37°C, were tested. Change in hyaluronan
molecular weight was observed by size-exclusion chromatography.
Hyaluronan degradation and molecular weight were estimated
from the retention times observed.
Results: Hyaluronan molecular weight of end-products showed
that hyaluronan suffers degradation when it is used together with
iodinated contrast media. The decrease in molecular weight was
higher in incubated samples, with a loss in molecular weight of 27-
29%, while samples not incubated showed a decrease of around
19-23%. In fact, differences of 4.6% (0.5 ml iodinated contrast
medium), 5.3% (0.75 ml iodinated contrast medium) and 9.3%
(1 ml iodinated contrast medium) were found between the same
sample subjected and not subjected to temperature for 24 hours.
These values therefore exerted signiﬁcant differences between
incubated and non-incubated samples, but no differences were
found among the volumes of iodinated contrast medium assayed.
Conclusions: It is proposed that the components of the iodinated
contrast medium analysed may interact with hyaluronan molecule,
breaking the glycosidic bonds between its monomers and pro-
ducing signiﬁcant degradation, which could result in a reduction
of clinical efﬁcacy. The results of clinical studies conducted with-
out taking into account this interaction should be considered with
caution.
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Purpose: TIMP-3 inhibits all the major cartilage-degrading metal-
loproteases, and multiple lines of evidence indicate that it protects
cartilage. Addition of the protein to cartilage explants prevents
cytokine-induced degradation, and intra-articular injection reduces
cartilage damage in the rat medial meniscal tear model of os-
teoarthritis. Conversely, TIMP-3 knockout mice spontaneously de-
velop cartilage lesions. While the results with injected TIMP-3 are
encouraging, frequent injections are required because the protein
is rapidly cleared. To facilitate the therapeutic use of recombinant
TIMP-3, we are investigating the clearance mechanism. Follow-
ing reports that blocking the LRP-1 scavenger receptor causes
an accumulation of TIMP-3, we asked whether TIMP-3 binds di-
rectly to LRP-1 and whether blocking this interaction is sufﬁcient
to promote TIMP-3 accumulation. We also sought to conﬁrm the
proposed mechanism for TIMP-3 clearance by evaluating accu-
mulation in cultures of LRP-1 deﬁcient cells and by using confocal
microscopy to visualize internalization of the protein.
Methods: Various sequences from the ecto-domain of LRP-1 were
